Cigna's 84.5% Medical Ratio Splits From the Medicare Advantage Trend Story

Cigna's medical care ratio ran to 84.5% in the second quarter of 2026, seven points below Humana's 91.2% and five points below Elevance Health's 89.7% (The Cigna Group, July 30, 2026; Humana, July 29, 2026).

That gap is not a commercial carrier having a good quarter. It is where 2026's cost-trend pressure is actually concentrated, and it is concentrated almost entirely in Medicare Advantage.

Key Takeaways

• 84.5% medical care ratio, seven points below Humana's 91.2% and five points below Elevance's 89.7%, on results reported within 48 hours of each other.
• The year-over-year comparison is against 83.2%, and Cigna attributes the rise to lapping higher ACA risk-adjustment benefits recorded in 2025 rather than to underlying utilization.
• Lower surgical and outpatient spend is the driver management named, the line item that swings hardest as deferred-care catch-up completes.
• Stop-loss frequency was stable at multiple attachment points, which argues the favorability is not large-claim timing due to reverse in the back half.
• PwC puts 2027 group trend at 9% and Segal at 9.9%, both well above what Cigna's commercial book is currently realizing.

The 84.5% Print and What Moved It

Cigna Healthcare's medical care ratio rose to 84.5% from 83.2%. The company attributed that comparison primarily to lapping higher ACA risk-adjustment benefits recorded in the Individual and Family Plans business in the second quarter of 2025, not to utilization deterioration.

Segment revenue reached $11.8 billion, up 10%, and Cigna Healthcare's pretax adjusted earnings were $1,276 million, keeping the segment on pace with a raised full-year floor of at least $4,550 million. Total company revenue was $71.7 billion, adjusted earnings per share $7.78, and the board raised full-year adjusted EPS guidance to at least $30.45, up $0.10 from $30.35.

The driver CFO Ann Dennison named is the notable part: not pharmacy, not primary care, but softer outpatient spending and specifically lower surgical volume. Medical costs came in "slightly favorable to expectations... reflecting lower outpatient trends, including lower surgical spend" (Cigna Q2 2026 earnings call).

CEO Brian Evanko described the wider environment differently in the same call: "We continue to see high single digit type cost trends, persistently elevated cost trend levels, not a significant deceleration and no acceleration." Both statements hold at once. Full-year guidance of 83.7% to 84.7% sits with its midpoint below the quarter's actual, which is not the posture of a company extrapolating the favorability forward.

Four Carriers, Two Trend Regimes

Carrier	Q2 2026 medical/benefit ratio	Year-over-year change	Book weighting
Cigna Healthcare	84.5%	+130 bps	Commercial, specialty, IFP
UnitedHealth	86.7%	−270 bps	Diversified, MA and commercial
Elevance Health	89.7%	+80 bps	Government-heavy, Medicaid and Medicare
Humana	91.2%	In line with guidance	Medicare Advantage-concentrated

UnitedHealth's ratio fell to 86.7% from 89.4%, which Forbes attributed to benefit redesign, pricing discipline and continued exits from unprofitable ACA and Medicare Advantage markets. Elevance's benefit expense ratio ran to 89.7%, up 80 basis points, on "elevated medical cost trends in Government businesses offset in part by improved Individual ACA performance" (Elevance Health, July 14, 2026). Humana's Insurance segment benefit ratio came in at 91.2% as individual Medicare Advantage membership rose roughly 25% and consolidated revenue reached $40.9 billion.

The closer a book sits to Medicare Advantage, the hotter the ratio. A spread of nearly 700 basis points between Cigna and Humana, on results 48 hours apart, is wide enough to change how the 2027 trend conversation is framed. There is no single 2026 cost trend number; there are two regimes running at once, split roughly by payer type.

Part of the spread is structural rather than cyclical. Commercial group plans carry member cost-sharing materially higher than the near-first-dollar coverage typical of MA supplemental designs, which dampens paid claims relative to allowed cost. Commercial populations skew younger and are experience-rated at each renewal, a faster repricing lever than the annual CMS bid cycle. And MA reimbursement runs off a Medicare fee-for-service benchmark that has itself been running hot on physician and outpatient facility updates.

Structure does not carry 700 basis points on its own. Cigna's own commentary points to a population effect. Employer-sponsored members who deferred elective procedures during 2023 and 2024 appear to have largely completed that catch-up, while MA's older and more acute population keeps generating the surgical and inpatient volume behind Humana's and Elevance's ratios. The read is not that cost trend is moderating, but that it moderated first, and furthest, where cost-sharing is highest and repricing fastest.

The favorability also does not look reserve-driven. Dennison walked through the stop-loss book, the segment most exposed to high-dollar claimant volatility, and reported "stable frequency trends in high-cost claimants across multiple attachment point levels." Specific stop-loss is where a trend acceleration surfaces first, in the tail of the claim distribution before it reaches the aggregate ratio. Stability there argues against the print being large-claim timing.

The Levers That Do Not Repeat

Two of the quarter's cost levers carry their own expiry. Evernorth's Specialty and Care Services posted pretax adjusted earnings of $1,054 million, up 22%, on Evernorth revenue of $61.5 billion, up 6%. Specialty generic penetration "exceeded 80% for newer products during the quarter," alongside "moderating GLP-1 growth as coverage levels slightly declined."

Cigna flagged that the specialty generic and biosimilar benefit is not expected to recur at the same level in the third and fourth quarters. That matches how a generic-conversion wave behaves: a step-function reduction concentrated in the first several quarters after exclusivity lapses, then a flatter savings profile once the addressable population has substituted. A 2027 pharmacy trend assumption extrapolated from the Q2 magnitude carries a diminishing substitution opportunity it has not priced.

The pharmacy model itself is changing under the same book. Pharmacy Benefit Services posted pretax adjusted earnings of $609 million, down year over year on "the previously discussed renewals and extensions of large client contracts." That is the visible cost of the shift toward Signature, the rebate-free model converting drugmaker rebates into upfront point-of-sale discounts. Cigna Healthcare adopts it for fully insured commercial clients in 2027, Evernorth for all pharmacy clients by 2028, at margins Evanko put "in that 4% range."

For a stop-loss underwriter that is a cleaner input and a harder conversation. Gross drug cost at dispensing becomes the number driving specific attachment exposure, rather than a net-of-rebate estimate that can differ from actual claimant experience. The headline pharmacy unit cost a plan sponsor sees under Signature runs higher even where net plan cost is unchanged, because the legacy quote carried the rebate offset in a separate reconciliation line.

Against all of that, the forward surveys sit well above the realized ratio. PwC put 2027 group medical trend at 9%, the highest in 17 years, driven partly by provider adoption of AI-enabled revenue optimization (PwC Health Research Institute, June 2026). Segal's 30th annual survey projected 9.9% medical and 11.5% prescription drug trend.

That gap between forward survey trend and realized ratio is the ordinary tension between manual and experience rating, sharper this cycle because the realized number is running so far below the surveys converging above it. A 2027 renewal locked off the low realized ratio alone understates the leveraged-trend exposure that reaches specific and aggregate attachment pricing once medical trend outpaces flat-dollar deductible growth.

Further Reading on actuary.info

• UnitedHealth and Elevance Split the Q2 2026 Managed-Care Recovery - How UNH's ratio improved to 86.7% while Elevance's climbed 80 basis points in the same reporting window.
• Aetna's 250bp MBR Drop Rode a $471M Reserve Reversal - The reserving mechanics behind CVS Health's own Medicare Advantage-weighted improvement.
• PwC's 2027 Group Medical Cost Trend Hits 9%, a 17-Year High - The forward trend benchmark Cigna's cooler Q2 print sits against.
• Segal's 2027 Survey Pegs Medical Trend at 9.9%, With Rx Still Ahead at 11.5% - The manual-versus-experience credibility question stop-loss actuaries face heading into 2027 renewals.
• Stop-Loss's Leveraged Trend: Flat Deductibles Meet Rising Claims - The attachment-point mechanics behind why a moderating aggregate trend does not necessarily moderate specific stop-loss exposure.